

Readiness of the drug candidate for COVID19 for India								Drug potential for India			
Scoring Scale	See Section B for scoring scale	See Section C for scoring scale	See Section D for scoring scale	See Section E for scoring scale	See Section F for scoring scale	See Section G for scoring scale	See Section H for scoring scale	See Section K for scoring scale	See Section K for scoring scale	See Section K for scoring scale	Scoring Scale
Drug candidate	Strength of scientific evidence on mechanism of action	Importance of mechanism of action and target	Strength of results at pre-clinical stage	Availability of Human Safety Data demonstrated through clinical studies	Clarity and certainty on formulations, method of administration, drug delivery and bioavailability for COVID19	Progress of clinical trials for COVID-19 (*outcomes as concluded by authors of published data)	Clarity and degree of certainty about supply chain and manufacturability in India	SCORE: READINESS (for India)	Outcome of clinical trials	SCORE: DRUG POTENTIAL (for India)	Drug candidate
<a href="#">Chloroquine</a>	3	4	4	5	3	4	5	79%	2	54%	<a href="#">Chloroquine</a>
<a href="#">Hydroxychloroquine</a>	3	4	4	5	3	5	5	81%	2	54%	<a href="#">Hydroxychloroquine</a>
<a href="#">Remdesivir</a>	3	5	4	3	2	2	3	60%	No data yet	Awaiting CT data	<a href="#">Remdesivir</a>
<a href="#">Lopinavir/Ritonavir</a>	3	5	3	5	4	3	5	78%	1	34%	<a href="#">Lopinavir/Ritonavir</a>
<a href="#">Favipiravir</a>	3	5	4	5	4	4	3	79%	4	73%	<a href="#">Favipiravir</a>
<a href="#">Baloxavir Marboxil</a>	2	1	3	5	2	2	3	46%	No data yet	Awaiting CT data	<a href="#">Baloxavir Marboxil</a>
<a href="#">Darunavir</a>	2	2	2	5	4	3	5	61%	1	34%	<a href="#">Darunavir</a>
<a href="#">Ribavirin + IFN beta</a>	3	2	2	4	4	2	3	55%	No data yet	Awaiting CT data	<a href="#">Ribavirin + IFN beta</a>
<a href="#">Galidesivir</a>	2	4	3	2	1	1	1	35%	No data yet	Awaiting CT data	<a href="#">Galidesivir</a>
<a href="#">Oseltamivir</a>	2	1	2	5	4	2	5	52%	1	34%	<a href="#">Oseltamivir</a>
<a href="#">Umifenovir(**)</a>	3	4	3	5	4	4	1	62%	3	42%	<a href="#">Umifenovir</a>
<a href="#">Camostat mesylate</a>	4	5	4	5	4	2	1	63%	No data yet	Awaiting CT data	<a href="#">Camostat mesylate</a>
<a href="#">Ruxolitinib</a>	4	4	2	5	4	2	3	65%	No data yet	Awaiting CT data	<a href="#">Ruxolitinib</a>
<a href="#">Interferon beta</a>	4	4	3	5	4	2	3	69%	No data yet	Awaiting CT data	<a href="#">Interferon beta</a>
<a href="#">Tocilizumab</a>	4	5	3	5	4	4	3	79%	4	73%	<a href="#">Tocilizumab</a>
<a href="#">Ustekinumab</a>	1	1	1	5	1	1	3	29%	No data yet	Awaiting CT data	<a href="#">Ustekinumab</a>
<a href="#">Nigericin</a>	2	3	2	1	1	1	2	31%	No data yet	Awaiting CT data	<a href="#">Nigericin</a>
<a href="#">Teicoplanin</a>	4	4	4	5	1	1	5	57%	No data yet	Awaiting CT data	<a href="#">Teicoplanin</a>
<a href="#">Ivermectin</a>	3	3	4	5	1	1	5	53%	No data yet	Awaiting CT data	<a href="#">Ivermectin</a>

Source: TFORD-COVID19-India (c) Venture Center, 2020

(\*\*) CT for prophylaxis